Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
API-CAT: reduced-dose versus full-dose apixaban for extended treatment of cancer-associated venous thromboembolism
NL-OMON54840Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apixaban in venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), sponsored by Assistance publique - Hôpitaux de Paris. Started Dec 2019; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON54840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54840.